Literature DB >> 31731983

Treatment of Drug-Susceptible Tuberculosis.

Beth Shoshana Zha1, Payam Nahid2.   

Abstract

Mycobacterium tuberculosis is a major public health concern and requires prompt treatment. Goals of treatment include curing the individual patient and protecting the community from ongoing tuberculosis transmission. To achieve durable cure, regimens must include multiple agents given concurrently and in a manner to ensure completion of therapy. This article focuses on preferred regimens of drug-susceptible tuberculosis under current guidelines by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America and World Health Organization. In addition, topics including patient centered care, poor treatment outcomes, and adverse effects are also discussed.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug-susceptible Mycobacterium tuberculosis; HIV and Mycobacterium tuberculosis co-infection; M tuberculosis treatment supervision and patient-centered care; Mycobacterium tuberculosis treatment regimen

Year:  2019        PMID: 31731983     DOI: 10.1016/j.ccm.2019.07.006

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  5 in total

1.  Role of Treatment Adherence, Doctor-Patient Trust, and Communication in Predicting Treatment Effects Among Tuberculosis Patients: Difference Between Urban and Rural Areas.

Authors:  Liang Du; Ruiheng Wu; Xu Chen; Jia Xu; Haoqiang Ji; Ling Zhou
Journal:  Patient Prefer Adherence       Date:  2020-11-24       Impact factor: 2.711

Review 2.  Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment.

Authors:  Radha Gopalaswamy; Sivakumar Shanmugam; Rajesh Mondal; Selvakumar Subbian
Journal:  J Biomed Sci       Date:  2020-06-17       Impact factor: 8.410

Review 3.  A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.

Authors:  Siqin He; Jiajia Gui; Kun Xiong; Meiwan Chen; Huile Gao; Yao Fu
Journal:  J Nanobiotechnology       Date:  2022-03-03       Impact factor: 10.435

4.  Screening performance of C-reactive protein for active pulmonary tuberculosis in HIV-positive patients: A systematic review with a meta-analysis.

Authors:  Andreea-Daniela Meca; Adina Turcu-Stiolica; Maria Bogdan; Mihaela-Simona Subtirelu; Relu Cocoș; Bogdan Silviu Ungureanu; Beatrice Mahler; Catalina-Gabriela Pisoschi
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

Review 5.  Drug hypersensitivity reactions in Asia: regional issues and challenges.

Authors:  Bernard Yu-Hor Thong; Michaela Lucas; Hye-Ryun Kang; Yoon-Seok Chang; Philip Hei Li; Min Moon Tang; James Yun; Jie Shen Fok; Byung-Keun Kim; Mizuho Nagao; Iris Rengganis; Yi-Giien Tsai; Wen-Hung Chung; Masao Yamaguchi; Ticha Rerkpattanapipat; Wasu Kamchaisatian; Ting Fan Leung; Ho Joo Yoon; Luo Zhang; Amir Hamzah Abdul Latiff; Takao Fujisawa; Francis Thien; Mariana C Castells; Pascal Demoly; Jiu-Yao Wang; Ruby Pawankar
Journal:  Asia Pac Allergy       Date:  2020-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.